Page 4 - Aural Analytics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Medable announced today that it is now partnering with Aural Analytics to test and develop remote digital data tools and harmonization...

24 Apr 2021 With disease-modifying treatments for Alzheimer’s disease potentially on the cusp of approval, there will be pressing demand for quick, simple ways to screen patients and determine if they have amyloid plaque in their brains. The current gold-standard diagnostics used in research—amyloid PET scans and cerebrospinal fluid biomarkers—are expensive, invasive, or not readily available to many patients. With that in mind, the Global Alzheimer’s Platform has launched Bio-Hermes, a collaborative study with 10 different technology companies that will assess how accurately low-cost...

Aural Analytics, Inc. and Healint, Pte. Ltd. Partner on Integration of Speech Analytics into Healint’s Suite of Clinical Trials and Widely Used Consumer Applications By Staff 4 hours ago The partnership will enable clinical trials and the collection of large, deeply phenotyped data-sets to better inform patient outcomes in Migraine, Multiple Sclerosis, Parkinson’s and other diseases SCOTTSDALE, ARIZ. & SINGAPORE–(BUSINESS WIRE)–Aural Analytics, Inc., and Healint Pte. Ltd. announced today they have entered into a strategic partnership to embed speech collection and analytics into Hea...

VeraSci Partners with Aural Analytics to Incorporate Speech Analytics into Pathway eCOA Platform News provided by Share this article Share this article DURHAM, N.C., March 17, 2021 /PRNewswire/ -- VeraSci — a global clinical research company offering eClinical software, translation services, and expertise in endpoints and assessments — is pleased to announce a new partnership with Aural Analytics, Inc., a global leader in speech analytics for clinical research. VeraSci has embedded the Aural Analytics' A2E™ speech analytics mobile application SDK and web API into the Pathway eCOA plat...

Posted on 9670 Aural Analytics, Inc., the industry leader in speech neuroscience and speech analytics technologies, announced today the initiation of a multi-product pivotal study to demonstrate the safety and efficacy of its speech-based tools for measuring pulmonary function and speech motor function in amyotrophic lateral sclerosis (ALS). The company anticipates submitting the results of this multi-site, multi-language, 280 participant, prospective, blinded study to the U.S. Food and Drug Administration (FDA) in late 2021. The s...